GlobeNewswire

Immunicum presenterar data från det kliniska programmet DCP-001 vid European Hematology Association (EHA) 2021 Virtual Congress

Dela

Immunicum presenterar data från det kliniska programmet DCP-001 vid European Hematology Association (EHA) 2021 Virtual Congress

- Den pågående ADVANCE-II-studien, som utvärderar DCP-001 hos AML-patienter, närmar sig målet om 20 rekryterade patienter -

Immunicum AB (publ; IMMU.ST) presenterar idag kliniska data som visar DCP-001: s förmåga att inducera immunsvar mot ett brett spektrum av tumörassocierade antigener hos patienter med akut myeolisk leukemi (AML), samt prekliniska resultat av förbättrad effekt vid kombination av DCP -001 med etablerade AML-behandlingar, vid EHA 2021 Virtual Congress, som hålls 9–17 juni 2021. Sammanfattningen av dessa presentationer har kommunicerats tidigare. E-posters finns att tillgå på såväl konferensens som företagets webbplats.

"De data som presenteras vid EHA-konferensen styrker vår uppfattning om att DCP-001 potentiellt kan förbättra den dåliga behandlingsprognosen för AML-patienter genom varaktig tumörkontroll och förlängd klinisk remission", säger Jeroen Rovers, Chief Medical Officer på Immunicum. ”Vi är nära att nå målet för patientrekryteringen i vår pågående ADVANCE-II-studie som utvärderar DCP-001 hos AML-patienter med mätbar restsjukdom och ser fram emot att kunna presentera fler resultat från denna studie i slutet av året. Baserat på prekliniska data ser vi dessutom att DCP-001 har potential att förbättra behandlingsresultaten i kombination med 5-AZA och venetoclax, vilket är en etablerad behandlingsregim för patienter med AML i USA. ”

ADVANCE-II är en internationell, multicenter, öppen fas II-klinisk studie som utvärderar effekt och säkerhet i två olika doseringsregimer av Immunicums kandidat för canceråterfallsvaccin DCP-001 hos patienter med AML vilka är i fullständig remission men har en kvarvarande mätbar restsjukdom. Initiala data från studien som presenterades vid ASH 2020-mötet visade att behandling med DCP-001 är säker, tolereras väl och samtidigt kan påvisa tidiga tecken på effekt vad gäller konvertering av patienter till icke-mätbar restsjukdom, så kallad MRD-negativ status.

Bolaget följer tidigare kommunicerad tidplan och kommer att kunna presentera ytterligare data i slutet av året.

E-posters som presenteras vid EHA 2021 Virtual Congress kommer att finnas tillgängliga för registrerade deltagare via Virtual Congress-plattformen från och med 09:00 fredagen den 11 juni samt på Immunicums webbplats. 

För mer information, vänligen kontakta:

Erik Manting
Chief Executive Officer
Telefon: +31 713 322 627
E-mail: ir@immunicum.com

investerarrelationer:

Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telefon: +46 8 732 8400
E-mail: ir@immunicum.com

pressfrågor:

Eva Mulder and Sophia Hergenhan
Trophic Communications
Telefon: +49 175 222 57 56
E-mail: immu@trophic.eu

Om Immunicum AB (publ)
Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. Med kompletterande terapeutiska angreppssätt i klinisk Fas II-utveckling baserade på intratumoral immunaktivering och canceråterfallsvaccin (relapse vaccine) är bolagets mål att förbättra överlevnad och livskvaliteten för en stor grupp cancerpatienter. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Supersapiens Powered by Abbott’s Libre Sense Glucose Sport Biosensor Announces Garmin Integration22.6.2021 16:30:00 CEST | Press release

New Connect IQ app gives athletes timely glucose levels on their bike computer and wrist, allowing for real-time adjustments to sustain peak performance Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbott’s Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin®. The Supersapiens training ecosystem empowers athletes to optimize fueling, maximize training, and increase performance gains. The integration will provide select users with a compatible Garmin smartwatch or Edge® cycling computer with real-time glucose visibility allowing them to go faster longer. The Supersapiens app can be downloaded now from the Connect IQ™ store. A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled sports continuous glucose monitor (CGM) — the Abbott Libre Sense Glucose Sport Biosensor. Supersapiens offers

Painter 2022: Must-Have Upgrade for Professional Artists Delivers a Faster, More Powerful Digital Painting Experience22.6.2021 15:01:00 CEST | Press release

Offering unprecedented performance, a streamlined workflow, and improved layer productivity, Painter 2022 makes it easier than ever for artists to create exceptional work OTTAWA, June 22, 2021 (GLOBE NEWSWIRE) -- Painter 2022 responds to users’ top requests and delivers a must-have upgrade by expanding creative possibilities. Designed for Windows 10 and macOS, this powerful and creative digital painting software adds enhancements that focus on accelerating workflows, boosting brush performance, and improving layer productivity to offer a game-changing digital art studio for today’s professional and aspiring artists. “We know the critical role Painter plays in professional artists’ workflows and are honored to be part of the creative process of bringing some of pop culture's most iconic movies, characters and games to life,” said Chris Pierce, Director of Product for Photo and Digital Arts at Corel. “With this version we focused on our customers’ top requests and whether it’s improvemen

IMCD N.V. shareholders adopt all resolutions at AGM22.6.2021 13:55:00 CEST | Press release

ROTTERDAM, The Netherlands (22 June 2021) – IMCD N.V. (hereafter “IMCD” or the “Company”) announces that all resolutions proposed to the shareholders at the Company’s Annual General Meeting (“AGM”) held today were adopted. This includes the adoption of the financial statements for the year 2020 and approval of the dividend proposal of EUR 1.02 per share in cash. The dividend calendar is as follows: Thursday 24 June 2021 - Ex-dividend date Friday 25 June 2021 - Record date Monday 28 June 2021 - Payment date Further resolutions included the reappointment of Deloitte Accountants B.V. as external auditor for the year 2021. The 2020 Remuneration Report received a positive advisory vote with over 94% of voted casted in favor of the report. Details of the Annual General Meeting, including the voting results, are available at IMCD’s corporate website. Attached, please find the press release in pdf format. Attachment PR_IMCD 2021 AGM resolutions

About making of a mandatory share buy-back offer22.6.2021 13:25:00 CEST | Press release

Joint stock company “Olainfarm”, hereinafter referred to as - “the Company”, hereby informs that on the 22nd of June, 2021 Joint stock company “AS “AB CITY””, registration number 40203174414, according to the clause 1 of the article 73 of the Financial Instrument Market Law, informed the Board of the Company about making of a mandatory share buy-back offer. The Board of the joint stock company “Olainfarm” will prepare conclusion and announce its opinion about the offer within terms set by the Financial Instrument Market Law after an advertisement regarding making of a share buy-back offer is published. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email: janis.dubrovskis@olainfarm.com

Verisk’s AIR Updates Its Terrorism Model to More Comprehensively Model Damage from Conventional Bomb Blast Attacks22.6.2021 12:11:00 CEST | Press release

BOSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that it has updated its Terrorism Model for the United States to more comprehensively model the extent of damage from conventional bomb blast attacks. Starting with the size and location of the bomb, the model propagates the appropriate blast intensity within a built environment from the exterior to the interior of buildings to yield damage and loss estimates, including property damage and workers’ compensation, and personal injury. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “When terrorists use conventional weapons—the effects of which tend to be highly localized—they are likely to be targeting specific buildings or facilities,” said Tao Lai, vice president, research, AIR Worldwide. “The amount of damage that occurs at or near the site of an attack depends on a wide variety of factors. In addition to the type of weapon used, the surrounding buildings, building dimensions and blast intens

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS22.6.2021 11:07:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-06-22Loan2311 Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,020Volume bought, SEK mln500Number of bids6Number of accepted bids2Average yield0.034 %Lowest accepted yield0.033 %Highest yield0.034 %% accepted at lowest yield 56.82 Auction date2021-06-22 Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,000Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield0.219 %Lowest accepted yield0.219 %Highest yield0.219 %% accepted at lowest yield 100.00 Auction date2021-06-22 Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln750 +/- 350 Volume offered, SEK mln1,000Volume bought, SEK mln750Number of bids3Number of accepted bids1Average yield0.623 %Lowest accepted yield0.623 %Highest yield0.623 %% accepted at lowest yield 100.00